1. From the Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California-San Francisco/Mt. Zion Comprehensive Cancer Center, University of California-San Francisco (MRC, JMB, DPL, PRC), San Francisco, the David Geffen School of Medicine and School of Public Health, University of California-Los Angeles (MSL), Los Angeles, California, and TAP Pharmaceutical Products, Inc. (SSM, JMH), Lake Forest, Illinois